Category: Biotechnology

Over 12% of US adults have used a GLP-1 drug, such as semaglutide, highlighting its widespread use. The complex process of how is semaglutide manufactured involves a multi-step journey, combining advanced biotechnology with precise chemical modifications to create a stable and effective therapeutic peptide.

More than 21 antibody therapeutics were granted a first approval in at least one country during 2024 [1.2.3]. So, **what is the new monoclonal antibody drug?** These lab-made proteins are revolutionizing treatment for cancer, autoimmune disorders, and infectious diseases by targeting specific cells [1.8.1, 1.8.4].

The first FDA-approved monoclonal antibody (mAb) for therapeutic use, muromonab-CD3, was approved in 1986 for preventing organ transplant rejection, marking a new era of targeted medicine. Since this historic milestone, a diverse and growing range of FDA approved monoclonal antibody therapies has revolutionized treatment paradigms across various diseases.

Every year, pharmaceutical companies process millions of liters of donated human plasma to create vital, life-saving medicines. This specialized and complex manufacturing process, known as fractionation, enables the extraction of essential proteins to produce therapies for a wide array of rare, chronic, and life-threatening conditions.

As of 2024, nearly 200 monoclonal antibodies have been approved for treating diseases, with many more in development [1.7.1]. This raises a common question for patients and caregivers alike: what does the ending umab mean and what does it signify about the medication?

Since the first monoclonal antibody drug was approved in 1986, this class of biologics has revolutionized medicine by offering highly targeted therapies. So, when would you use monoclonal antibodies, and for which conditions is this advanced treatment indicated?

The global market for monoclonal antibody therapies was valued at over $200 billion in 2022, signaling a transformative shift in medicine. These lab-engineered proteins, often called mAbs, provide highly targeted treatments for a vast range of conditions, leaving many to ask: what does mAbs help with?

Serratiopeptidase accounts for approximately 60% of worldwide enzyme sales due to its wide range of industrial and therapeutic uses [1.2.1]. This article explains the complex bio-industrial answer to 'how to make serratiopeptidase,' detailing its journey from microbe to medication.

The global biologics market was valued at over $461 billion in 2022 and is projected to surpass $1 trillion by 2030 [1.10.1]. This guide answers the key question: **What class of medications are biologics?** and explores why they are a revolutionary force in modern medicine.

Millions of patients worldwide depend on plasma-derived therapies for survival and improved quality of life. Answering the question, **what medicine is made from plasma?**, involves understanding how donated human plasma is processed into critical treatments for numerous rare and chronic conditions.